The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk assessment based on the Risk Index for Serious Adverse Events (SAEs) in phase I trials.
 
Shigehiro Koganemaru
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Taiho Pharmaceutical
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Kenichi Harano
No Relationships to Disclose
 
Hideaki Takahashi
Honoraria - Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Takahiro Kogawa
Research Funding - Daiichi Sankyo
 
Yoichi Naito
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; Meiji Seika Kaisha; Novartis; Roche; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; Lilly; Merck Serono; Nippon Kayaku
 
Takahiro Sakai
No Relationships to Disclose
 
Yukie Kimura
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst)
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)